Management of an Incidental Liver Mass

Surgical Clinics of North America

Volumn 90, Issue 4, 2010, Pages 699-718

  Boutros, Cherif ^a   Katz, Steven C ^a   Espat, N Joseph ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Benign liver tumors; Hepatocellular carcinoma; Incidental liver mass; Liver metastases

Indexed keywords

FLUORODEOXYGLUCOSE F 18; VINYL CHLORIDE;

BILE DUCT CARCINOMA; BILIARY HAMARTOMA; CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC APPROACH ROUTE; ECHOGRAPHY; ENVIRONMENTAL EXPOSURE; GROUPS BY AGE AND SEX; HEPATIC ADENOMA; INCIDENTAL FINDING; LIPOMA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CYST; LIVER FOCAL NODULAR HYPERPLASIA; LIVER HEMANGIOMA; LIVER HYDATID CYST; LIVER RESECTION; LIVER TUMOR; MEDICAL DECISION MAKING; MEDICAL HISTORY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIODIAGNOSIS; REVIEW; RISK FACTOR; STEROID THERAPY; BIOPSY; CLASSIFICATION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HUMAN; INCIDENCE; LIVER NEOPLASMS;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; INCIDENCE; INCIDENTAL FINDINGS; LIVER NEOPLASMS; RISK FACTORS;

EID: 77954627813     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2010.04.005     Document Type: Review

References (118)

1. Furtado C.D., Aguirre D.A., Sirlin C.B., et al. Whole-body CT screening: spectrum of findings and recommendations in 1192 patients. Radiology 2005, 237(2):385-394.
2. Hoe A.L., Royle G.T., Taylor I. Breast liver metastases-incidence, diagnosis and outcome. J R Soc Med 1991, 84(12):714-716.
3. Zinser J.W., Hortobagyi G.N., Buzdar A.U., et al. Clinical course of breast cancer patients with liver metastases. J Clin Oncol 1987, 5(5):773-782.
4. Power D.G., Healey-Bird B.R., Kemeny N.E. Regional chemotherapy for liver-limited metastatic colorectal cancer. Clin Colorectal Cancer 2008, 7(4):247-259.
5. Khatri V.P., Chee K.G., Petrelli N.J. Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg Oncol 2007, 16(1):71-83.
6. Pawlik T.M., Choti M.A. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007, 11(8):1057-1077.
7. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231(1):51-58.
8. Katz S.C., Pillarisetty V.G., Bleier J.I., et al. Liver sinusoidal endothelial cells are insufficient to activate T cells. J Immunol 2004, 173(1):230-235.
9. Tang L., Yang J., Liu W., et al. Liver sinusoidal endothelial cell lectin, LSECtin, negatively regulates hepatic T-cell immune response. Gastroenterology 2009, 137(4):1498-1508. e1-5.
10. Baum J.K., Bookstein J.J., Holtz F., et al. Possible association between benign hepatomas and oral contraceptives. Lancet 1973, 2(7835):926-929.
11. Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology 1977, 73(2):386-394.
12. Edmondson H.A., Henderson B., Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976, 294(9):470-472.
13. Rooks J.B., Ory H.W., Ishak K.G., et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979, 242(7):644-648.
14. Christopherson W.M., Mays E.T., Barrows G. Hepatocellular carcinoma in young women on oral contraceptives. Lancet 1978, 2(8079):38-39.
15. Malt R.A., Hershberg R.A., Miller W.L. Experience with benign tumors of the liver. Surg Gynecol Obstet 1970, 130(2):285-291.
16. Motsay G.J., Gamble W.G. Clinical experience with hepatic adenomas. Surg Gynecol Obstet 1972, 134(3):415-418.
17. Wilson J.D. Androgen abuse by athletes. Endocr Rev 1988, 9(2):181-199.
18. Creagh T.M., Rubin A., Evans D.J. Hepatic tumours induced by anabolic steroids in an athlete. J Clin Pathol 1988, 41(4):441-443.
19. Blair A., Kazerouni N. Reactive chemicals and cancer. Cancer Causes Control 1997, 8(3):473-490.
20. Simonato L., L'Abbe K.A., Andersen A., et al. A collaborative study of cancer incidence and mortality among vinyl chloride workers. Scand J Work Environ Health 1991, 17(3):159-169.
21. Lawrence T.S., Robertson J.M., Anscher M.S., et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995, 31(5):1237-1248.
22. Wands J. Hepatocellular carcinoma and sex. N Engl J Med 2007, 357(19):1974-1976.
23. Nakatani T., Roy G., Fujimoto N., et al. Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Jpn J Cancer Res 2001, 92(3):249-256.
24. Stipa F., Yoon S.S., Liau K.H., et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 2006, 106(6):1331-1338.
25. Roayaie S., Haim M.B., Emre S., et al. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol 2000, 7(10):764-770.
26. Yamanaka N., Tanaka T., Tanaka W., et al. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 1997, 79(8):1509-1515.
27. Schwartz M. Liver transplantation: the preferred treatment for early hepatocellular carcinoma in the setting of cirrhosis?. Ann Surg Oncol 2007, 14(2):548-552.
28. Shah S.A., Greig P.D., Gallinger S., et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 2006, 202(2):275-283.
29. Harrison P.M. Prevention of bile duct cancer in primary sclerosing cholangitis. Ann Oncol 1999, 10(Suppl 4):208-211.
30. Jones D.E., Metcalf J.V., Collier J.D., et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997, 26(5):1138-1142.
31. Deugnier Y.M., Guyader D., Crantock L., et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993, 104(1):228-234.
32. Ryder S.D., Koskinas J., Rizzi P.M., et al. Hepatocellular carcinoma complicating autoimmune hepatitis: role of hepatitis C virus. Hepatology 1995, 22(3):718-722.
33. Kumagi T., Horiike N., Abe M., et al. Small hepatocellular carcinoma associated with Wilson's disease. Intern Med 2005, 44(5):439-443.
34. Karhunen P.J. Benign hepatic tumours and tumour like conditions in men. J Clin Pathol 1986, 39(2):183-188.
35. Volk M., Strotzer M., Lenhart M., et al. Frequency of benign hepatic lesions incidentally detected with contrast-enhanced thin-section portal venous phase spiral CT. Acta Radiol 2001, 42(2):172-175.
36. Schwartz L.H., Gandras E.J., Colangelo S.M., et al. Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology 1999, 210(1):71-74.
37. Kuszyk B.S., Bluemke D.A., Urban B.A., et al. Portal-phase contrast-enhanced helical CT for the detection of malignant hepatic tumors: sensitivity based on comparison with intraoperative and pathologic findings. AJR Am J Roentgenol 1996, 166(1):91-95.
38. Eberhardt S.C., Choi P.H., Bach A.M., et al. Utility of sonography for small hepatic lesions found on computed tomography in patients with cancer. J Ultrasound Med 2003, 22(4):335-343. [quiz: 345-6].
39. Ohto M., Kato H., Tsujii H., et al. Vascular flow patterns of hepatic tumors in contrast-enhanced 3-dimensional fusion ultrasonography using plane shift and opacity control modes. J Ultrasound Med 2005, 24(1):49-57.
40. Tidebrant G., Asztely M., Lukes P., et al. Comparison of non-enhanced, bolus enhanced, and delayed scanning techniques in computed tomography of hepatic tumours. Acta Radiol 1990, 31(2):161-166.
41. Honda H., Matsuura Y., Onitsuka H., et al. Differential diagnosis of hepatic tumors (hepatoma, hemangioma, and metastasis) with CT: value of two-phase incremental imaging. AJR Am J Roentgenol 1992, 159(4):735-740.
42. Foley W.D. Liver: surgical planning. Eur Radiol 2005, 15(Suppl 4):D89-D95.
43. Valette P.J., Pilleul F., Crombe-Ternamian A. MDCT of benign liver tumors and metastases. Eur Radiol 2003, 13(Suppl 5):M31-M41.
44. Scherzinger A.L., Hendee W.R. Basic principles of magnetic resonance imaging-an update. West J Med 1985, 143(6):782-792.
45. Turner D.A. Nuclear magnetic resonance in oncology. Semin Nucl Med 1985, 15(2):210-223.
46. Braga L., Guller U., Semelka R.C. Modern hepatic imaging. Surg Clin North Am 2004, 84(2):375-400.
47. Semelka R.C., Helmberger T.K. Contrast agents for MR imaging of the liver. Radiology 2001, 218(1):27-38.
48. Schultz J.F., Bell J.D., Goldstein R.M., et al. Hepatic tumor imaging using iron oxide MRI: comparison with computed tomography, clinical impact, and cost analysis. Ann Surg Oncol 1999, 6(7):691-698.
49. Choi J.Y., Lee K.S., Kwon O.J., et al. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol 2005, 23(30):7654-7659.
50. Kojima S., Zhou B., Teramukai S., et al. Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: the Nishidai clinic study. Eur J Cancer 2007, 43(12):1842-1848.
51. Katz S.C., Shaha A. PET-associated incidental neoplasms of the thyroid. J Am Coll Surg 2008, 207(2):259-264.
52. Smith T.J., Kemeny M.M., Sugarbaker P.H., et al. A prospective study of hepatic imaging in the detection of metastatic disease. Ann Surg 1982, 195(4):486-491.
53. Cosgrove D. The advances are significant improvements in both the microbubbles used as contrast agents and in the software that allows their selective detection. Eur Radiol 2004, 14(Suppl 8):1-3.
54. Albrecht T., Blomley M.J., Cosgrove D.O., et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999, 353(9164):1579-1583.
55. Choi B.I., Kim A.Y., Lee J.Y., et al. Hepatocellular carcinoma: contrast enhancement with Levovist. J Ultrasound Med 2002, 21(1):77-84.
56. Skjoldbye B., Pedersen M.H., Struckmann J., et al. Improved detection and biopsy of solid liver lesions using pulse-inversion ultrasound scanning and contrast agent infusion. Ultrasound Med Biol 2002, 28(4):439-444.
57. Scaife C.L., Ng C.S., Ellis L.M., et al. Accuracy of preoperative imaging of hepatic tumors with helical computed tomography. Ann Surg Oncol 2006, 13(4):542-546.
58. Matsuo M., Kanematsu M., Inaba Y., et al. Pre-operative detection of malignant hepatic tumours: value of combined helical CT during arterial portography and biphasic CT during hepatic arteriography. Clin Radiol 2001, 56(2):138-145.
59. Kehagias D., Metafa A., Hatziioannou A., et al. Comparison of CT, MRI and CT during arterial portography in the detection of malignant hepatic lesions. Hepatogastroenterology 2000, 47(35):1399-1403.
60. Schmidt J., Strotzer M., Fraunhofer S., et al. Intraoperative ultrasonography versus helical computed tomography and computed tomography with arterioportography in diagnosing colorectal liver metastases: lesion-by-lesion analysis. World J Surg 2000, 24(1):43-47. [discussion: 48].
61. Mahfouz A.E., Hamm B., Mathieu D. Imaging of metastases to the liver. Eur Radiol 1996, 6(5):607-614.
62. Kim Y.K., Kwak H.S., Kim C.S., et al. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid. J Magn Reson Imaging 2009, 30(2):437-443.
63. Vogl T.J., Schwarz W., Blume S., et al. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol 2003, 13(2):262-272.
64. Biagini C. Radiol Med 1986, 72(6):379-392. [in Italian].
65. Buetow P.C., Pantongrag-Brown L., Buck J.L., et al. Focal nodular hyperplasia of the liver: radiologic-pathologic correlation. Radiographics 1996, 16(2):369-388.
66. Royal H.D., Israel O., Parker J.A., et al. Scintigraphy of hepatic hemangiomas: the value of Tc-99m-labeled red blood cells: concise communication. J Nucl Med 1981, 22(8):684-687.
67. Krausz Y., Levy M., Antebi E., et al. Liver hemangioma. A perioperative Tc-99m RBC SPECT correlation. Clin Nucl Med 1997, 22(1):35-37.
68. Guze B.H., Hawkins R.A. Utility of the SPECT Tc-99m labeled RBC blood pool scan in the detection of hepatic hemangiomas. Clin Nucl Med 1989, 14(11):817-818.
69. Yapar Z., Kibar M., Yapar AF., et al. The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up. Nucl Med Commun 2010, 31(1):59-66..
70. Pace L., Nicolai E., Klain M., et al. Diagnostic value of FDG PET/CT imaging. Q J Nucl Med Mol Imaging 2009, 53(5):503-512.
71. Orlacchio A., Schillaci O., Fusco N., et al. Role of PET/CT in the detection of liver metastases from colorectal cancer. Radiol Med 2009, 114(4):571-585.
72. Kinkel K., Lu Y., Both M., et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002, 224(3):748-756.
73. Desai D.C., Zervos E.E., Arnold M.W., et al. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol 2003, 10(1):59-64.
74. Rydzewski B., Dehdashti F., Gordon B.A., et al. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. AJR Am J Roentgenol 2002, 178(2):353-358.
75. Ruers T.J., Langenhoff B.S., Neeleman N., et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002, 20(2):388-395.
76. Salem N., MacLennan G.T., Kuang Y., et al. Quantitative evaluation of 2-deoxy-2[F-18]fluoro-D-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol 2007, 9(3):135-143.
77. Delbeke D., Pinson C.W. 11C-acetate: a new tracer for the evaluation of hepatocellular carcinoma. J Nucl Med 2003, 44(2):222-223.
78. MacManus M.P., Hicks R.J., Matthews J.P., et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001, 50(2):287-293.
79. Nasuti J.F., Gupta P.K., Baloch Z.W. Diagnostic value and cost-effectiveness of on-site evaluation of fine-needle aspiration specimens: review of 5,688 cases. Diagn Cytopathol 2002, 27(1):1-4.
80. Stewart C.J., Coldewey J., Stewart I.S. Comparison of fine needle aspiration cytology and needle core biopsy in the diagnosis of radiologically detected abdominal lesions. J Clin Pathol 2002, 55(2):93-97.
81. Ohlsson B., Nilsson J., Stenram U., et al. Percutaneous fine-needle aspiration cytology in the diagnosis and management of liver tumours. Br J Surg 2002, 89(6):757-762.
82. Kulesza P., Torbenson M., Sheth S., et al. Cytopathologic grading of hepatocellular carcinoma on fine-needle aspiration. Cancer 2004, 102(4):247-258.
83. Kuo F.Y., Chen W.J., Lu S.N., et al. Fine needle aspiration cytodiagnosis of liver tumors. Acta Cytol 2004, 48(2):142-148.
84. Riemann B., Menzel J., Schiemann U., et al. Ultrasound-guided biopsies of abdominal organs with an automatic biopsy system. A retrospective analysis of the quality of biopsies and of hemorrhagic complications. Scand J Gastroenterol 2000, 35(1):102-107.
85. Kucharczyk W., Weisbrod G.L., Cooper J.D., et al. Cardiac tamponade as a complication of thin-needle aspiration lung biopsy. Chest 1982, 82(1):120-121.
86. Kosugi C., Furuse J., Ishii H., et al. Needle tract implantation of hepatocellular carcinoma and pancreatic carcinoma after ultrasound-guided percutaneous puncture: clinical and pathologic characteristics and the treatment of needle tract implantation. World J Surg 2004, 28(1):29-32.
87. Wanebo H.J., Semoglou C., Attiyeh F., et al. Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg 1978, 135(1):81-85.
88. Fahy B.N., D'Angelica M., DeMatteo R.P., et al. Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention. Ann Surg Oncol 2009, 16(2):361-370.
89. Yoon S.S., Charny C.K., Fong Y., et al. Diagnosis, management, and outcomes of 115 patients with hepatic hemangioma. J Am Coll Surg 2003, 197(3):392-402.
90. Unal O., Sakarya M.E., Arslan H., et al. Hepatic cavernous hemangiomas: patterns of contrast enhancement on MR fluoroscopy imaging. Clin Imaging 2002, 26(1):39-42.
91. Olcott E.W., Li K.C., Wright G.A., et al. Differentiation of hepatic malignancies from hemangiomas and cysts by T2 relaxation times: early experience with multiply refocused four-echo imaging at 1.5 T. J Magn Reson Imaging 1999, 9(1):81-86.
92. Heiken J.P. Distinguishing benign from malignant liver tumours. Cancer Imaging 2007, 7(Spec No A):S1-14.
93. Whitehouse R.W. Computed tomography attenuation measurements for the characterization of hepatic haemangiomas. Br J Radiol 1991, 64(767):1019-1022.
94. Quinn S.F., Benjamin G.G. Hepatic cavernous hemangiomas: simple diagnostic sign with dynamic bolus CT. Radiology 1992, 182(2):545-548.
95. Jenkins R.L., Johnson L.B., Lewis W.D. Surgical approach to benign liver tumors. Semin Liver Dis 1994, 14(2):178-189.
96. Mitchell D.G., Saini S., Weinreb J., et al. Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging. Radiology 1994, 193(1):49-57.
97. Bioulac-Sage P., Balabaud C., Wanless I.R. Diagnosis of focal nodular hyperplasia: not so easy. Am J Surg Pathol 2001, 25(10):1322-1325.
98. Mortele K.J., Praet M., Van Vlierberghe H., et al. CT and MR imaging findings in focal nodular hyperplasia of the liver: radiologic-pathologic correlation. AJR Am J Roentgenol 2000, 175(3):687-692.
99. Cherqui D., Rahmouni A., Charlotte F., et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995, 22(6):1674-1681.
100. Kehagias D., Moulopoulos L., Antoniou A., et al. Focal nodular hyperplasia: imaging findings. Eur Radiol 2001, 11(2):202-212.
101. Diament M.J., Parvey L.S., Tonkin I.L., et al. Hepatoblastoma: technetium sulfur colloid uptake simulating focal nodular hyperplasia. AJR Am J Roentgenol 1982, 139(1):168-171.
102. Tanasescu D.E., Waxman A.D., Hurvitz C. Scintigraphic findings mimicking focal nodular hyperplasia in a case of hepatoblastoma. Clin Nucl Med 1991, 16(4):236-238.
103. Fabre A., Audet P., Vilgrain V., et al. Histologic scoring of liver biopsy in focal nodular hyperplasia with atypical presentation. Hepatology 2002, 35(2):414-420.
104. Makhlouf H.R., Abdul-Al H.M., Goodman Z.D. Diagnosis of focal nodular hyperplasia of the liver by needle biopsy. Hum Pathol 2005, 36(11):1210-1216.
105. Vilgrain V., Lewin M., Vons C., et al. Hepatic nodules in Budd-Chiari syndrome: imaging features. Radiology 1999, 210(2):443-450.
106. Dokmak S., Paradis V., Vilgrain V., et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009, 137(5):1698-1705.
107. Ribeiro A., Burgart L.J., Nagorney D.M., et al. Management of liver adenomatosis: results with a conservative surgical approach. Liver Transpl Surg 1998, 4(5):388-398.
108. Koffron A., Geller D., Gamblin T.C., et al. Laparoscopic liver surgery: shifting the management of liver tumors. Hepatology 2006, 44(6):1694-1700.
109. Gaines P.A., Sampson M.A. The prevalence and characterization of simple hepatic cysts by ultrasound examination. Br J Radiol 1989, 62(736):335-337.
110. Chauveau D., Fakhouri F., Grunfeld J.P. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol 2000, 11(9):1767-1775.
111. Pinto M.M., Kaye A.D. Fine needle aspiration of cystic liver lesions. Cytologic examination and carcinoembryonic antigen assay of cyst contents. Acta Cytol 1989, 33(6):852-856.
112. Gharbi H.A., Hassine W., Abdesselem K. Ann Radiol (Paris) 1985, 28(1):31-34. [in French].
113. Charny C.K., Jarnagin W.R., Schwartz L.H., et al. Management of 155 patients with benign liver tumours. Br J Surg 2001, 88(6):808-813.
114. Shimizu S., Takayama T., Kosuge T., et al. Benign tumors of the liver resected because of a diagnosis of malignancy. Surg Gynecol Obstet 1992, 174(5):403-407.
115. Mahfouz A.E., Hamm B., Wolf K.J. Peripheral washout: a sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions. Radiology 1994, 190(1):49-52.
116. Danet I.M., Semelka R.C., Leonardou P., et al. Spectrum of MRI appearances of untreated metastases of the liver. AJR Am J Roentgenol 2003, 181(3):809-817.
117. Liu C.L., Fan S.T., Lo C.M., et al. Hepatic resection for incidentaloma. J Gastrointest Surg 2004, 8(7):785-793.
118. Bruix J., Sherman M. Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.